Quest Diagnostics is Thursday's IBD Stock Of The Day. Shares are lingering in a buy zone, helped by a Texas court's ruling.

BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares.

Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Quest ...

Redburn Atlantic analyst Jamie Clark initiated coverage of Quest Diagnostics (DGX) with a Buy rating and $195 price target Don't Miss Our End ...

Diving into Analyst Ratings: An In-Depth Exploration The analysis of recent analyst actions sheds light on the perception of Quest Diagnostics by financial experts. The following summary presents ...

This was the stock's second consecutive day of losses.

Stay informed and make data-driven decisions with our Ratings Table. Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company ...